Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $104.25 USD
Change Today +0.72 / 0.70%
Volume 662.3K
NVS On Other Exchanges
Symbol
Exchange
Xetra
New York
OTC US
Mexico
SIX Swiss Ex
SIX Swiss Ex
Frankfurt
As of 8:04 PM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Lichtstrasse 35

Basel, 4056

Switzerland

Phone: 41 61 324 11 11

Fax:

ovan is approved in approximately 100 countries worldwide. Exforge (valsartan and amlodipine besylate) is a single-pill combination of the ARB Diovan and the calcium channel blocker amlodipine besylate. It is available in approximately 100 countries. Exforge HCT (valsartan, amlodipine besylate and hydrochlorothiazide) is a single pill combining three widely prescribed high blood pressure treatments: an ARB, a calcium channel blocker and a diuretic (hydrochlorothiazide). Exforge HCT was approved in the EU and the U.S. in 2009, and is available in approximately 60 countries. Voltaren/Cataflam (diclofenac sodium/potassium/resinate/free acid) is a non-steroidal anti-inflammatory drug (NSAID) for the relief of symptoms in rheumatic diseases, such as rheumatoid arthritis and osteoarthritis, and for various other inflammatory and pain conditions. Voltaren/Cataflam is available in approximately 140 countries. This product is marketed by the Pharmaceuticals Division in various dosage forms, including tablets, drops, suppositories, ampoules and topical therapy. In addition, in various countries, its Sandoz Division markets generic versions of the product, its Alcon Division markets Voltaren for ophthalmic indications, and its OTC (over-the-counter) Division markets low-dose oral forms and the topical therapy of Voltaren as over-the-counter products. Ritalin, Ritalin LA, Focalin and Focalin XR (methylphenidate HCl, methylphenidate HCl extended release, dexmethylphenidate HCl and dexmethylphenidate HCl extended release) are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children. Ritalin is also indicated for narcolepsy. Ritalin is available in approximately 70 countries. Ritalin LA is available in approximately 30 countries. Focalin include the active d-isomer of methylphenidate and therefore requires half the dose of Ritalin. Focalin and Focalin XR are available in the U.S. Tegretol (carbamazepine) is indicated for epilepsy (partial seizures, generalized tonic clonic and mixed forms of seizures), acute mania and maintenance treatment of bipolar disorders, alcohol withdrawal syndrome, trigeminal neuralgia, glossopharyngeal neuralgia, painful diabetic neuropathy, diabetes insipidus centralis and polyuria and polydipsia of neurohormonal origin. It is available in 129 countries. Cell and Gene Therapies Unit The company has created a dedicated unit focused on the development and commercialization of Cell and Gene Therapies. The Cell and Gene Therapies Unit intends to develop a new approach to treating or potentially curing some patients suffering from various life-threatening diseases, including blood-borne cancers, sickle cell disease, thalassemias and other diseases of the blood by replacing, repopulating or resetting the immune system. Markets The Pharmaceuticals Division sells products in approximately 155 countries worldwide. The company sells its prescription drugs primarily to wholesale and retail drug distributors, hospitals, clinics, government agencies and managed healthcare providers. Research and Development The Pharmaceuticals division’s research and development expenditure included $7.3 billion in 2014. ALCON The Alcon Division engages in the research, development, manufacturing and marketing of eye care products worldwide. The company offers products serving the full lifecycle of patient needs across eye diseases, vision conditions and refractive errors. To meet the needs of ophthalmologists, surgeons, optometrists, opticians and physician specialists, the company operates with three franchises: Surgical, Ophthalmic Pharmaceuticals and Vision Care. The company’s products are available in approximately 180 markets. The Alcon division works together with the Novartis Institutes for BioMedical Research (NIBR), the company’s pharmaceutical research organization. This collaboration allows the Alcon division to leverage the resources of NIBR in an effort to discover and expand ophthalmic pharmaceutical research targets and to develop chemical and biologic compounds for the potential treatment of diseases of the eye, with a particular focus on di

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVS:US $104.25 USD +0.72

NVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $112.85 USD +0.39
Johnson & Johnson $101.15 USD +0.02
Merck & Co Inc $59.70 USD +0.24
Pfizer Inc $34.44 USD +0.14
Roche Holding AG SFr.279.40 CHF -3.10
View Industry Companies
 

Industry Analysis

NVS

Industry Average

Valuation NVS Industry Range
Price/Earnings 24.2x
Price/Sales 4.7x
Price/Book 3.3x
Price/Cash Flow 13.7x
TEV/Sales 4.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-SPONSORED ADR, please visit www.novartis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.